Physician profile
Rajesh Kumar Davit
NPI 1194745612
$141.33
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2021: $20.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.55 | 2019 | |
| Pfizer INC. | $24.25 | 2019-2021 | |
| Lilly USA, LLC | $23.35 | 2019 | |
| Glaxosmithkline, LLC. | $18.17 | 2019 | |
| Amgen INC. | $15.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.68 | 2019 | |
| Novo Nordisk INC | $11.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.44 | 2019 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Davit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.